{"pub": "marketwatch", "url": "https://marketwatch.com/articles/biogen-stock-climbed-on-surprise-alzheimers-drug-news-the-effects-could-be-lasting-51571826600", "downloaded_at": "2019-10-23 10:55:03.168527+00:00", "title": "Biogen Stock Climbed on Surprise Alzheimer\u2019s Drug News. The Effects Could Be Lasting.", "language": "en", "text": "Biogen pulled a rabbit out of its hat on Tuesday morning, announcing that the Alzheimer\u2019s drug that investors had written off as a failure would get an unexpected second chance at Food and Drug Administration approval.\n\nBut while the drug could be a major revenue driver for Biogen (ticker: BIIB), SVB Leerink analyst Geoffrey Porges said in an interview on Tuesday afternoon that it would represent a significant drain on the health care system at a time when pharmaceutical companies are already being criticized over high drug...", "description": "The company announced that the Alzheimer\u2019s drug that investors had written off as a failure would get an unexpected second chance at Food and Drug Administration approval.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DH037_Biogen_OR_20191022094944.jpg", "published_at": "2019-10-23"}